Financial reports
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
25 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
Current reports
8-K
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
19 Mar 24
8-K
Departure of Directors or Certain Officers
11 Jan 24
8-K
Relmada Therapeutics Provides Corporate Update
4 Jan 24
8-K
Departure of Directors or Certain Officers
3 Jan 24
8-K
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver MeetingĀ® 2023
11 Oct 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders October 10 th , 2023
10 Oct 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders October 4 th , 2023
4 Oct 23
8-K
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
20 Sep 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
21 Jun 23
S-3ASR
Automatic shelf registration
7 Apr 22
424B5
Prospectus supplement for primary offering
10 Dec 21
424B5
Prospectus supplement for primary offering
8 Dec 21
S-8
Registration of securities for employees
6 Jul 21
S-3
Shelf registration
12 Aug 20
424B5
Prospectus supplement for primary offering
15 May 20
424B5
Prospectus supplement for primary offering
5 Dec 19
424B5
Prospectus supplement for primary offering
3 Dec 19
424B3
Prospectus supplement
1 Nov 19
Proxies
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
DEF 14A
Definitive proxy
11 Apr 22
PRE 14A
Preliminary proxy
31 Mar 22
DEF 14A
Definitive proxy
31 Mar 21
DEFA14A
Additional proxy soliciting materials
28 Feb 20
DEF 14A
Definitive proxy
31 Jan 20
DEF 14A
Definitive proxy
9 Jan 19
PRE 14A
Preliminary proxy
21 Dec 18
DEF 14A
Definitive proxy
15 Dec 17
Other
EFFECT
Notice of effectiveness
24 Aug 20
CORRESP
Correspondence with SEC
19 Aug 20
UPLOAD
Letter from SEC
18 Aug 20
EFFECT
Notice of effectiveness
1 Nov 19
EFFECT
Notice of effectiveness
1 Nov 19
CORRESP
Correspondence with SEC
30 Oct 19
CORRESP
Correspondence with SEC
28 Oct 19
UPLOAD
Letter from SEC
25 Oct 19
EFFECT
Notice of effectiveness
24 Oct 19
CORRESP
Correspondence with SEC
21 Oct 19
Ownership
SC 13G/A
PERCEPTIVE ADVISORS LLC
6 Mar 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
SERGIO TRAVERSA
31 Jan 24
4
Maged Shenouda
31 Jan 24
4
Chuck Ence
31 Jan 24
4
SERGIO TRAVERSA
19 Dec 23
4
Maged Shenouda
19 Dec 23